Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00924950 · ClinicalTrials.gov registry record · Phase 4
Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis
A Phase 4 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 4
- Development phase
- 35
- Enrollment target
NCT00924950 is a Phase 4 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 35 participants.
The verdict
NCT00924950, a Phase 4 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether using Taclonex ointment under a hydrogel patch is more effective than using the ointment alone in treating psoriasis. Taclonex ointment is currently FDA approved for use on psoriasis. The hydrogel patch is a type of adhesive pad and contains no medications. It is currently FDA approved and has been shown to be safe and virtually free of side effects. The hypothesis is that psoriatic plaques which are treated with Taclonex ointment under a hydrogel patch will be more effectively treated compared to psoriatic plaques treated with Taclonex alone.
Interventions
- DRUG Taclonex Ointment and Hydrogel Patch
- DRUG Taclonex Ointment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2009-06 |
| Est. Completion | 2009-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00924950
The ClinicalTrials.gov registry entry for NCT00924950 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Taclonex Ointment and Hydrogel Patch is the first listed.
NCT00924950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00924950 about?
NCT00924950 is a clinical study titled "Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis". The purpose of this study is to determine whether using Taclonex ointment under a hydrogel patch is more effective than using the ointment alone in treating psoriasis. Taclonex ointment is currently FDA approved for use on psoriasis. The hydrogel patch is a type of adhesive pad and contains no medic...
What is the current status of trial NCT00924950?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 35 participants. The study started on 2009-06. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00924950?
The interventions under investigation include: Taclonex Ointment and Hydrogel Patch (DRUG), Taclonex Ointment (DRUG).
Who is sponsoring clinical trial NCT00924950?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.